These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36839908)

  • 1. Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn's Disease: A Cross-Sectional Multicentric Latin American Study.
    de Souza LR; Magro DO; Teixeira FV; Parra RS; Miranda EF; Féres O; Saad-Hossne R; Soares Prates Herrerias G; Nisihara RM; Coy CSR; Sassaki LY; Kotze PG
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional study.
    Sirmai L; Pelletier AL; Gault N; Zallot C; Bouguen G; Bouchard D; Roland Nicaise P; Peyneau M; Sironneau S; Bittencourt MC; Petitcollin A; Fernandez P; Roblin X; Siproudhis L; Abramowitz L
    World J Gastroenterol; 2022 Mar; 28(9):961-972. PubMed ID: 35317057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.
    Yarur AJ; Jain A; Hauenstein SI; Quintero MA; Barkin JS; Deshpande AR; Sussman DA; Singh S; Abreu MT
    Inflamm Bowel Dis; 2016 Feb; 22(2):409-15. PubMed ID: 26752470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
    Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
    Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.
    Juncadella A; Papamichael K; Vaughn BP; Cheifetz AS
    Dig Dis Sci; 2018 Nov; 63(11):3067-3073. PubMed ID: 30006816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn's disease.
    Szymanska E; Dadalski M; Grajkowska W; Szymanska S; Pronicki M; Kierkus J
    Prz Gastroenterol; 2017; 12(1):44-48. PubMed ID: 28337236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center.
    Ahmed Z; Venkata K; Zhang N; Malik TA
    Gastroenterology Res; 2019 Oct; 12(5):245-251. PubMed ID: 31636774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn's disease.
    Chen L; Lu Z; Kang D; Feng Z; Li G; Sun M; Liu Z; Wu W; Fang L
    Front Pharmacol; 2022; 13():913720. PubMed ID: 36034848
    [No Abstract]   [Full Text] [Related]  

  • 11. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
    Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab.
    Mizoshita T; Tanida S; Ozeki K; Katano T; Shimura T; Mori Y; Kubota E; Kataoka H; Kamiya T; Joh T
    Case Rep Gastroenterol; 2016; 10(2):283-91. PubMed ID: 27462198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
    Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease.
    Ozeki K; Tanida S; Mizoshita T; Tsukamoto H; Ebi M; Mori Y; Kataoka H; Kamiya T; Joh T
    Case Rep Gastroenterol; 2012 Sep; 6(3):765-71. PubMed ID: 23341799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
    Gordon M; Taylor K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
    Kato M; Sugimoto K; Ikeya K; Takano R; Matsuura A; Miyazu T; Ishida N; Tamura S; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Hanai H
    PLoS One; 2021; 16(7):e0254548. PubMed ID: 34242369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease.
    Hinojosa J; Muñoz F; Martínez-Romero GJ
    Dig Dis; 2019; 37(6):444-450. PubMed ID: 31039560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement.
    Mizoshita T; Tanida S; Tsukamoto H; Ozeki K; Katano T; Nishiwaki H; Ebi M; Mori Y; Kubota E; Kataoka H; Kamiya T; Joh T
    Gastroenterol Res Pract; 2014; 2014():687257. PubMed ID: 24829572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.